SK bioscience, the biopharmaceutical arm of South Korea's SK Group, said on Wednesday it has achieved a "final victory" in a ...

SEOUL, April 23 (Yonhap) -- SK bioscience Co., the biopharmaceutical arm of South Korea's SK Group, said Wednesday it has ...

South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna (Nasdaq: MRNA) over key ...

SK Bioscience announced Wednesday that it has secured a definitive legal victory in its patent invalidation suit against Moderna, successfully challenging the biotech giant’s Korean patent related to ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

Got a new vaccine? Korea can make it for you.

The drugmaker will also showcase new data with a 21-valent pneumococcal vaccine developed in collaboration with SK Biosciences that is due to start phase 3 testing next year and could compete with ...

SK. Joseph M. Blondeau, MSc, PhD, RSM(CCM), SM(AAM), SM(ASCP), FCCP, Head of Clinical Microbiology, Royal University Hospital and Saskatoon Health Region, and Adjunct Professor of Microbiology and ...